PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $12.25.

A number of research firms have issued reports on PYPD. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a report on Wednesday, February 11th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Roth Mkm decreased their price target on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Finally, Citigroup reissued a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PYPD. AIGH Capital Management LLC lifted its holdings in shares of PolyPid by 26.1% during the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock valued at $5,828,000 after buying an additional 277,844 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid in the fourth quarter worth $451,000. Lumbard & Kellner LLC purchased a new stake in PolyPid during the second quarter valued at $135,000. Jane Street Group LLC bought a new position in PolyPid in the fourth quarter valued at about $66,000. Finally, XTX Topco Ltd boosted its position in PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the last quarter. Institutional investors own 26.47% of the company’s stock.

PolyPid Price Performance

PYPD stock opened at $4.18 on Friday. PolyPid has a 1 year low of $2.30 and a 1 year high of $5.12. The firm has a 50-day moving average of $4.41 and a 200 day moving average of $3.84. The company has a market cap of $66.46 million, a P/E ratio of -1.85 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). On average, equities research analysts expect that PolyPid will post -1.79 earnings per share for the current fiscal year.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.